Page last updated: 2024-12-05

ochratoxin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ochratoxin A: structure in first source & in Merck, 9th ed, #6549 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ochratoxin A : A phenylalanine derivative resulting from the formal condensation of the amino group of L-phenylalanine with the carboxy group of (3R)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1H-2-benzopyran-7-carboxylic acid (ochratoxin alpha). It is among the most widely occurring food-contaminating mycotoxins, produced by Aspergillus ochraceus, Aspergillus carbonarius and Penicillium verrucosum. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID442530
CHEMBL ID589366
CHEBI ID7719
SCHEMBL ID15105
MeSH IDM0085108

Synonyms (66)

Synonym
CBIOL_002012
nsc-201422
n-(((3r)-5-chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl)-3-phenyl-l-alanine
CHEBI:7719 ,
(2s)-2-{[(3r)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1h-2-benzopyran-7-carbonyl]amino}-3-phenylpropanoic acid
(-)-n-((5-chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl)-3-phenylalanine
n-{[(3r)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1h-isochromen-7-yl]carbonyl}-l-phenylalanine
n-[(3r)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1h-2-benzopyran-7-carbonyl]-l-phenylalanine
(r)-n-((5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1h-2-benzopyran-7-yl)carbonyl)phenylalanine
ACON1_001268
MEGXM0_000357
BIO1_000298
BIO1_001276
BIO1_000787
SMP2_000132
ACON0_000200
OTA ,
alanine, n-((5-chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl)-3-phenyl-, (-)-
phenylalanine - ochratoxin a
l-phenylalanine, n-((5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1h-2-benzopyran-7-yl)carbonyl)-, (r)-
ochratoxin a
C09955
ochratoxin a, from petromyces albertensis, >=98% (hplc)
ochratoxin a-bsa conjugate from aspergillus ochraceus
NCGC00162403-02
NCGC00162403-01
NCGC00162403-03
inchi=1/c20h18clno6/c1-10-7-12-14(21)9-13(17(23)16(12)20(27)28-10)18(24)22-15(19(25)26)8-11-5-3-2-4-6-11/h2-6,9-10,15,23h,7-8h2,1h3,(h,22,24)(h,25,26
(r)-n-((5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1h-2-benzopyran-7-yl)-carbonyl)-l-phenylalanine
(-)-n-((5-chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl-3-phenylalanine
BRD-K39944607-001-01-4
CHEMBL589366
3r14s-ochratoxin a
n-[[(3r)-5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1h-2-benzopyran-7-yl]carbonyl]-l-phenylalanine
NCGC00162403-04
n-[(3r)-(5-chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl]-l-phenylalanine
(2s)-2-{[(3r)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1h-2-benzopyran-7-yl]formamido}-3-phenylpropanoic acid
gtpl4672
ochratoxin a [mi]
ochratoxin a [hsdb]
ochratoxin a [iarc]
(r)-n-((5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1h-2-benzopyran-7-yl)carbonyl)-l-phenylalanine
SCHEMBL15105
ochratoxin a, aspergillus ochraceus
l-phenylalanine, n-[(5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1h-2-benzopyran-7-yl)carbonyl]-, (r)-
alanine, n-[(5-chloro-8-hydroxy-3-methyl-1-oxo-7-isochromanyl)carbonyl]-3-phenyl-, (-)-
AKOS024456512
mfcd00078079
DTXSID7021073
ochratoxin a, purum, >=98.0% (tlc), from aspergillus ochraceus
ochratoxin a, reference material, from aspergillus ochraceus
bdbm50485598
J-017922
NCGC00162403-05
n-[(5-chloro-3,4-dihydro-8-hydroxy-3-methyl-1-oxo-1h-2-benzopyran-7-yl)carbonyl]phenylalanine, 9ci
ochratoxin a(ota)
(s)-2-((r)-5-chloro-8-hydroxy-3-methyl-1-oxoisochroman-7-carboxamido)-3-phenylpropanoic acid
ochratoxin a 10 microg/ml in acetonitrile:methanol
Q1885038
ochratoxin a 10 microg/ml in acetonitrile
(2~{s})-2-[[(3~{r})-5-chloranyl-3-methyl-8-oxidanyl-1-oxidanylidene-3,4-dihydroisochromen-7-yl]carbonylamino]-3-phenyl-propanoic acid
97u ,
ochratoxin a 100 microg/ml in methanol
ochratoxin a 10 microg/ml in methanol
ochratoxin a 2 microg/ml in methanol
03 - mycotoxin

Research Excerpts

Toxicity

Ochratoxin A (OTA) is a toxic metabolite produced by Aspergillus and Penicillium fungi commonly found in raw plant sources and other feeds. The study was designed to determine the toxic potential of three structurally related ochratoxins: och ratoxin A, ochRatoxin B (OTB) and heat-induced 3S-epimer of OTA (3S-OTA)

ExcerptReferenceRelevance
"The ability of activated charcoal to adsorb ochratoxin A (OA) in vitro and to reduce the toxic effects of OA in vivo when added to the diet of growing Leghorn chicks was studied."( Influence of dietary charcoal on ochratoxin A toxicity in Leghorn chicks.
Frohlich, AA; Marquardt, RR; Rotter, RG, 1989
)
0.28
" An attempt to prevent its toxic effects has been made using piroxicam, a non-steroidal anti-inflammatory drug (NSAID)."( Effect of piroxicam on the nephrotoxicity induced by ochratoxin A in rats.
Baudrimont, I; Betbeder, AM; Creppy, EE; Guilcher, J; Murn, M, 1995
)
0.29
" Citrinin was less toxic than ochratoxin A in all of the cell lines examined."( Toxicity evaluation of the mycotoxins, citrinin and ochratoxin A, using several animal cell lines.
Doi, E; Kitabatake, N; Trivedi, AB, 1993
)
0.29
" OTA has a number of toxic effects, the most prominent being nephrotoxicity."( Effect of superoxide dismutase and catalase on the nephrotoxicity induced by subchronical administration of ochratoxin A in rats.
Baudrimont, I; Betbeder, AM; Creppy, EE; Dirheimer, G; Gharbi, A; Pfohl-Leszkowicz, A, 1994
)
0.29
" Our results suggest that at least P450IIB1-dependent metabolism of OTA leads to its detoxication and that OTA itself may be toxic in some circumstances or that other pathways are responsible for its activation."( Effect of cytochrome P450 induction on the metabolism and toxicity of ochratoxin A.
Gelboin, HV; Omar, RF; Rahimtula, AD, 1996
)
0.29
"In common with many xenobiotics, metabolic activation and detoxification play crucial roles in the determination of a toxic response of animal species, including man, to exposure to mycotoxins."( Genetic implications in the metabolism and toxicity of mycotoxins.
Neal, GE, 1995
)
0.29
" To reduce or abolish the OTA-induced toxic effects, several mechanisms were investigated."( Prevention of nephrotoxicity of ochratoxin A, a food contaminant.
Baudrimont, I; Betbeder, AM; Creppy, EE, 1995
)
0.29
" The present study was designed to determine the toxic potential of three structurally related ochratoxins: ochratoxin A (OTA), ochratoxin B (OTB) and the heat-induced 3S-epimer of OTA (3S-OTA) recently discovered in roasted coffee and human serum."( Reduction of ochratoxin A toxicity by heat-induced epimerization. In vitro effects of ochratoxins on embryonic chick meningeal and other cell cultures.
Bruinink, A; Rasonyi, T; Sidler, C, 1997
)
0.3
" An attempt to prevent its toxic effect, mainly the inhibition of protein synthesis, has been made using aspartame (L-aspartyl-L-phenylalanine methyl ester) a structural analogue of both OTA and phenylalanine."( Reduction of the ochratoxin A-induced cytotoxicity in Vero cells by aspartame.
Baudrimont, I; Betbeder, AM; Creppy, EE, 1997
)
0.3
" The combination of these basic mechanisms with the unusual long plasma half-life time (35 days in non-human primates and in humans), the metabolisation of OTA into still active derivatives and glutathione conjugate both potentially reactive with cellular macromolecules including DNA could explain the multiple toxic effects, cytotoxicity, teratogenicity, genotoxicity, mutagenicity and carcinogenicity."( How aspartame prevents the toxicity of ochratoxin A.
Baudrimont, I; Creppy, EE, 1998
)
0.3
" Altered dosing strategy, but not seeding density, consistently influenced cytotoxicity: CIT was more toxic to cells when added at the time of seeding, whereas OA was more toxic when added 24 h after cultures were seeded."( Cytotoxicity of nephrotoxic fungal toxins to kidney-derived LLC-PK1 and OK cell lines.
Armstrong, CL; Bondy, GS, 1998
)
0.3
" Data show that OTA does not appear to exert a selective toxic dopaminergic cell action and that OTA-induced cytotoxicity and inhibition of cell differentiation were not prevented by exogenous glutathione."( Effects of ochratoxin A on cytotoxicity and cell differentiation in cultured rat embryonic cells.
Han, SY; Hong, JT; Jang, SJ; Kim, HS; Lee, RD; Oh, SD; Park, KL; Park, KS, 2000
)
0.31
" This mycotoxin is a frequent contaminant of human and animal food products, and is toxic to all animal species tested."( The role of oxidative stress in the ochratoxin A-mediated toxicity in proximal tubular cells.
de Groene, EM; Fink-Gremmels, J; Maas, RF; Nijmeijer, SM; Roestenberg, P; Schaaf, GJ, 2002
)
0.31
" Birds fed both toxins showed toxic additive effects, and no protection of any adsorbent was observed."( Evaluation of two mycotoxin binders to reduce toxicity of broiler diets containing ochratoxin A and T-2 toxin contaminated grain.
Avila, E; García, AR; Petrone, VM; Rosiles, R,
)
0.13
"Ochratoxin A (OTA), a mycotoxin frequently present in food and feedstuffs, produces a wide range of toxic effects, including cell death via lipid peroxidation."( Evaluation of the protective effects of alpha-tocopherol and retinol against ochratoxin A cytotoxicity.
Baldi, A; Bertasi, B; Carli, S; Cheli, F; Fusi, E; Losio, MN; Pavoni, E; Politis, I; Rebucci, R; Sangalli, L, 2004
)
0.32
" However, until now conflicting data have been presented regarding the role of biotransformation products in the adverse effects of OTA."( Metabolism-mediated cytotoxicity of ochratoxin A.
Bull, S; Fink-Gremmels, J; Simarro Doorten, AY; van der Doelen, MA, 2004
)
0.32
" The mechanisms that lead to toxic effects, such as immune toxicity, and carcinogenicity are complexe."( Synergistic effects of fumonisin B1 and ochratoxin A: are in vitro cytotoxicity data predictive of in vivo acute toxicity?
Baudrimont, I; Borracci, P; Carratù, MR; Chiarappa, P; Creppy, EE; Moukha, S, 2004
)
0.32
" Therefore, the question is justified whether such a combined intake of mycotoxins would lead to a possible higher risk for adverse health effects than the intake of one of these mycotoxins alone."( Combined toxic effects of mycotoxins.
Speijers, GJ; Speijers, MH, 2004
)
0.32
" The most pronounced adverse effect of OTA is hepatonephrotoxicity."( Protective role of melatonin in ochratoxin a toxicity in rat heart and lung.
Aydin, G; Okutan, H; Ozcelik, N,
)
0.13
" Our data indicate a new mechanistic explanation for the toxic actions induced by OTA, and they are notable with respect to a possible coexposition of the kidney to OTA and naturally occurring ERK1/2 inhibitors."( Proximal tubular toxicity of ochratoxin A is amplified by simultaneous inhibition of the extracellular signal-regulated kinases 1/2.
Gekle, M; Holzinger, H; Sauvant, C, 2005
)
0.33
"It has been shown that oxidative damage contributes to the wide range of toxic effects of the mycotoxin ochratoxin A (OTA)."( Effect of vitamin E and polyphenols on ochratoxin A-induced cytotoxicity in liver (HepG2) cells.
Augustin, K; Blank, R; Bösch-Saadatmandi, C; Hundhausen, C; Rimbach, G; Wolffram, S, 2005
)
0.33
"Ochratoxin-A (OTA) is a fungal metabolite with potential toxic effects on the central nervous system that have not yet been fully characterized."( Acute neurotoxic effects of the fungal metabolite ochratoxin-A.
Harbison, R; Reunova, O; Sánchez-Ramos, J; Sava, V; Velasquez, A, 2006
)
0.33
"Many adverse drug reactions are caused by the cytochrome P450 (CYP) dependent activation of drugs into reactive metabolites."( An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics.
Grossi, P; Kanter, Rd; Monaci, S; Monshouwer, M; Turlizzi, E; Vignati, L, 2005
)
0.33
" In order to assess whether honey can inhibit the toxic effect of mycotoxins, the present study was undertaken."( Effect of dietary honey on intestinal microflora and toxicity of mycotoxins in mice.
Abd El-Khalek, AB; Ezz El-Arab, AM; Girgis, SM; Hegazy, EM, 2006
)
0.33
" The aim of this study was to evaluate the ability of OTA to produce single-strand DNA breaks and oxidative DNA damage in the human renal proximal tubular epithelial cell line (HK-2), due to the fact that there is no study on human kidney cells as the toxic target."( Oxidative DNA damage induced by Ochratoxin A in the HK-2 human kidney cell line: evidence of the relationship with cytotoxicity.
Arbillaga, L; Azqueta, A; Ezpeleta, O; López de Cerain, A, 2007
)
0.34
" This implies that there is a dose below which no adverse health effects are expected to occur."( Ochratoxin A as a potential etiologic factor in endemic nephropathy: lessons from toxicity studies in rats.
Dekant, W; Hard, GC; Mally, A, 2007
)
0.34
" There were no significant differences in the sensitivity of neurons in early and late stage of differentiation and astrocytes to the toxic activity of this compound."( Developmental toxicity of Ochratoxin A in rat embryo midbrain micromass cultures.
Minta, M; Wilk-Zasadna, I, 2009
)
0.35
" Increased urinary glucose is a well-established indicator of kidney damage, and altered excretion of TCA cycle intermediates (citrate and 2-oxoglutarate) is found as a general response to toxic insult in many metabonomics studies."( Metabonomic study of ochratoxin a toxicity in rats after repeated administration: phenotypic anchoring enhances the ability for biomarker discovery.
Amberg, A; Dekant, W; Mally, A; Rached, E; Sieber, M; Wagner, S, 2009
)
0.35
"5) estimated by MTT reduction assay shows that BEA is three times more toxic than OTA."( Beauvericin and ochratoxin A genotoxicity evaluated using the alkaline comet assay: single and combined genotoxic action.
Darabos, D; Kasuba, V; Klarić, MS; Pepeljnjak, S; Rozgaj, R, 2010
)
0.36
" The number of OTA-induced neoplasms was similar in chicks given 25 ppm L-β-phenylalanine (PHE) in addition to 5 ppm OTA compared to chicks given only 5 ppm OTA, which showed that PHE cannot be used as a real protector against the carcinogenic or toxic effects of OTA in chicks."( Studies on carcinogenic and toxic effects of ochratoxin A in chicks.
Stoev, SD, 2010
)
0.36
"Ochratoxin A (OTA) is a toxic isocoumarin derivative produced by various species of mould which mainly grow on grain, coffee, and nuts."( Transcript and protein profiling analysis of OTA-induced cell death reveals the regulation of the toxicity response process in Arabidopsis thaliana.
Hao, J; Huang, K; Liang, Z; Luo, Y; Peng, X; Wang, Y; Xu, W; Zhang, Y; Zhao, W, 2012
)
0.38
" In addition, NAC could almost completely reverse the adverse effects of OTA at the protein level."( An iTRAQ-based mitoproteomics approach for profiling the nephrotoxicity mechanisms of ochratoxin A in HEK 293 cells.
Huang, K; Liang, R; Luo, Y; Shen, XL; Wang, Y; Xu, W; Zhang, Y; Zheng, J, 2013
)
0.39
" Several studies have been performed to try to counteract the adverse effects of oxygen radicals generated under OTA-exposure."( Toxicity of ochratoxin a and its modulation by antioxidants: a review.
Acquaviva, R; Barbagallo, I; Bognanno, M; Di Giacomo, C; Galvano, F; Sorrenti, V, 2013
)
0.39
" Some of the toxic effects of OTA are potentiated by other mycotoxins or other contaminants."( Ochratoxin A: developmental and reproductive toxicity-an overview.
Malir, F; Novotna, E; Ostry, V; Pfohl-Leszkowicz, A, 2013
)
0.39
" are toxic and hold a significant genotoxic efficacy at nanomolar concentrations."( Mycotoxins' activity at toxic and sub-toxic concentrations: differential cytotoxic and genotoxic effects of single and combined administration of sterigmatocystin, ochratoxin A and citrinin on the hepatocellular cancer cell line Hep3B.
Anninou, N; Chatzaki, E; Papachristou, F; Pitiakoudis, M; Simopoulos, C, 2014
)
0.4
"The aim of our study was to determine the efficacy of three different adsorbents, inorganic (modified zeolite), organic (esterified glucomannans) and mixed (inorganic and organic components, with the addition of enzymes), in protecting broilers from the toxic effects of ochratoxin A in feed."( Comparative investigation of the efficacy of three different adsorbents against OTA-induced toxicity in broiler chickens.
Jovanovic, M; Milićević, D; Nedeljković-Trailović, J; Resanović, R; Trailović, S; Vasiljevic, M, 2015
)
0.42
" Results indicate a higher toxic effect of the mycotoxins when they are co-exposed."( Cytotoxicity of the mycotoxins deoxynivalenol and ochratoxin A on Caco-2 cell line in presence of resveratrol.
Cano-Sancho, G; Fernández-Cruz, ML; González-Arias, CA; Ramos, AJ; Sanchis, V, 2015
)
0.42
" OTA is regarded as the most toxic family member, however, other ochratoxins or their metabolites and, in particular, ochratoxin mixtures or combinations with other mycotoxins may represent serious threats to human and animal health."( Comparative Ochratoxin Toxicity: A Review of the Available Data.
Bingle, LE; Heussner, AH, 2015
)
0.42
" In order to get better insight into the mechanism of its toxicity and on the several attempts made for prevention or attenuation of its toxic action, a detailed description is given on chemistry and toxicokinetics of this mycotoxin."( Ochratoxin A: Molecular Interactions, Mechanisms of Toxicity and Prevention at the Molecular Level.
Kőszegi, T; Poór, M, 2016
)
0.43
" However, an interaction with target molecules is a prerequisite for any observed adverse effect."( Structure-activity relationship of ochratoxin A and synthesized derivatives: importance of amino acid and halogen moiety for cytotoxicity.
Ferse, I; Gekle, M; Humpf, HU; Röhl, C; Rottkord, U; Rückschloss, U; Schulz, MC; Schwerdt, G, 2017
)
0.46
" Most metabolites of OTA are less toxic than OTA except OP-OTA."( Ochratoxin A: Toxicity, oxidative stress and metabolism.
Chen, D; Huang, L; Liu, A; Pan, Y; Peng, D; Tao, Y; Wang, X; Wang, Y; Xie, S; Xu, F; Yuan, Z, 2018
)
0.48
"The toxic effects of Ochratoxin A (OTA), a fungal secondary metabolite of the genera Aspergillus and Penicillium with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) a Parkinson inducing drug were investigated to evaluate the neurotoxic effects exerted by OTA."( Restorative effect of l-Dopa treatment against Ochratoxin A induced neurotoxicity.
Anand, T; Bhat, PV; Khanum, F; Mohan Manu, T, 2018
)
0.48
" 2'R-OTA, even at sub-toxic concentrations, increased the toxic action of OTA."( Interaction of 2'R-ochratoxin A with Serum Albumins: Binding Site, Effects of Site Markers, Thermodynamics, Species Differences of Albumin-binding, and Influence of Albumin on Its Toxicity in MDCK Cells.
Bálint, M; Cramer, B; Csepregi, R; Derdák, D; Faisal, Z; Hetényi, C; Humpf, HU; Kőszegi, T; Kunsági-Máté, S; Lemli, B; Poór, M; Sueck, F, 2018
)
0.48
" OTA was the least toxic mycotoxin and DON and BEA showed similar acute toxicity."( Cytotoxicity against fish and mammalian cell lines and endocrine activity of the mycotoxins beauvericin, deoxynivalenol and ochratoxin-A.
Fernández-Cruz, ML; García-Herranz, V; Navas, JM; Valdehita, A, 2019
)
0.51
"The multiple toxic effects of ochratoxin A (OTA) are a threat for human and animal."( Probiotic Bacillus subtilis CW14 reduces disruption of the epithelial barrier and toxicity of ochratoxin A to Caco-2 cells.
Liang, Z; Liu, J; Peng, M, 2019
)
0.51
" Furthermore, it was possible to discriminate toxicants acting at different time points during embryonic development and, therefore, responsible for distinct adverse effects on neural tube formation."( Accuracy, discriminative properties and reliability of a human ESC-based in vitro toxicity assay to distinguish teratogens responsible for neural tube defects.
De Geyter, C; Feutz, AC, 2019
)
0.51
"Mycotoxins, ochratoxin A (OTA), and citrinin (CTN) are toxic metabolites of filamentous fungi."( Safety evaluation of Ochratoxin A and Citrinin after 28 days repeated dose oral exposure to Wistar rats.
Ansari, KM; Arshad, M; Ayanur, A; Dev, I; Jagdale, PR; Singh, D, 2020
)
0.56
" Although predictions about the joint toxic effects of mycotoxins can be made from their individual toxicities, experimental data is still limited to allow a reliable hazard assessment."( Combined cytotoxic and genotoxic effects of ochratoxin A and fumonisin B
Alvito, P; Loureiro, S; Louro, H; Pinhão, M; Silva, MJ; Tavares, AM, 2020
)
0.56
" OTA presents a unique scenario in food safety, because it is known to be a potential risk; because heating may destroy it, but not completely; and because the hazard profile suggests it is not acutely toxic at the occurrence levels in coffee, although at high exposure levels, it is potentially nephrotoxic and carcinogenic in animal models."( Assessing the food safety risk of ochratoxin A in coffee: A toxicology-based approach to food safety planning.
Doepker, CL; Hawks, SE; Heintz, MM; Wikoff, DS, 2021
)
0.62
" Despite being associated with a range of adverse health effects, a comprehensive systems-level mechanistic understanding of the toxicity of OTA remains elusive."( An integrated systems-level model of ochratoxin A toxicity in the zebrafish (Danio rerio) embryo based on NMR metabolic profiling.
Alia, A; Bashirova, N; Berry, JP; Eeza, MNH; Matysik, J; Zuberi, Z, 2022
)
0.72
"Ochratoxin A (OTA) is a toxic metabolite produced by Aspergillus and Penicillium fungi commonly found in raw plant sources and other feeds."( Ochratoxin A as an alarming health threat for livestock and human: A review on molecular interactions, mechanism of toxicity, detection, detoxification, and dietary prophylaxis.
Arumugam, VA; Balasubramanian, B; Baskaran, R; Bhotla, HK; Issara, U; Liu, WC; Meyyazhagan, A; Mousavi Khaneghah, A; Pappuswamy, M; Pushparaj, K, 2022
)
0.72
" Additionally, the safe upper limits of OTA were estimated to be 677."( The multiple biotoxicity integrated study in grass carp (Ctenopharyngodon idella) caused by Ochratoxin A: Oxidative damage, apoptosis and immunosuppression.
Feng, L; Jiang, J; Jiang, WD; Kuang, SY; Liu, X; Liu, Y; Mi, HF; Tang, L; Wu, P; Zhang, L; Zhao, P; Zhou, XQ, 2022
)
0.72
" Our results show that OTA induced adverse effects in the hippocampus cells of adult mice brain tissue when administered in cumulative doses."( The Neurotoxic Effect of Ochratoxin-A on the Hippocampal Neurogenic Niche of Adult Mouse Brain.
Canto, A; Garcia Esparza, MA; Mateo, E; Miranda, M; Monroy Noyola, A; Soria, JM; Tonino, RPB, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis of curves of plasma level versus time suggests its distribution in two distinct body compartments."( Pharmacokinetics of ochratoxin A in animals.
Galtier, P, 1991
)
0.28
" The pharmacokinetic profiles of ochratoxin A in pigs and broilers were also investigated and discussed."( Contribution of pharmacokinetic computerized simulations in toxicological approach of ochratoxin A.
Alvinerie, M; Charpenteau, JL; Galtier, P,
)
0.13
" The pharmacokinetic characteristics of six analogs of OA including OA, OB (OA without chloride), OC (OA ethyl ester), and some metabolites, such as O alpha (OA without phenylalanine), OA-OH (hydroxylated OA), and a newly discovered form of OA, OP-OA (lactone opened ring of OA), were investigated in rats after a single intravenous administration of the compounds."( Pharmacokinetics of ochratoxin A and its metabolites in rats.
Crow, G; Frohlich, AA; Li, S; Marquardt, RR; Vitti, TG, 1997
)
0.3

Compound-Compound Interactions

ExcerptReferenceRelevance
"A novel, simple, and rapid method is presented for the analysis of aflatoxin B1, aflatoxin B2, and ochratoxin A in rice samples by dispersive liquid-liquid microextraction combined with LC and fluorescence detection."( Rapid analysis of aflatoxins B1, B2, and ochratoxin A in rice samples using dispersive liquid-liquid microextraction combined with HPLC.
Lai, XW; Liu, CL; Ruan, CQ; Sun, DL; Zhang, H, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" The biliary excretion and hepatic levels of [3H]tetracycline were decreased whereas bile flow did not vary and plasma bioavailability of radioactivity increased in comparison with control rats."( Incidence of experimental ochratoxicosis on hepatic disposition of [3H]tetracycline and chloramphenicol in rats.
Alvinerie, M; Galtier, P, 1983
)
0.27
" The bioavailability of the toxin was very high, 98%."( Toxicokinetics of ochratoxin A in rat following intratracheal administration.
Breitholtz-Emanuelsson, A; Fuchs, R; Hult, K, 1995
)
0.29
" In conclusion, CHA can reduce OTA concentrations in plasma as well as reducing nephrotoxicity, which may be attributed to a decrease of bioavailability and/or enterohepatic circulation of the toxin."( Dietary cholestyramine reduces ochratoxin A-induced nephrotoxicity in the rat by decreasing plasma levels and enhancing fecal excretion of the toxin.
Barriault, C; Bouchard, G; Frohlich, AA; Kerkadi, A; Marquardt, RR; Tuchweber, B; Yousef, IM, 1998
)
0.3
" Some studies suggest that esterified glucomannan derived from the cell wall of Saccharomyces cerevisiae is effective in reducing the bioavailability of at least some of the mycotoxins occurring in contaminated feed."( Efficacy of a commercial mycotoxin binder in alleviating effects of ochratoxin A, fumonisin B1, moniliformin and zearalenone in adult mink.
Bursian, SJ; Choi, I; Fernadez, G; Fernandez, G; Fitzgerald, SD; Leefers, K; Mitchell, RR; Moran, L; Murphy, PA; Rottinghaus, GE; Yamini, B, 2004
)
0.32
" Insufficient knowledge on the bioavailability may hamper an accurate risk assessment of ingested contaminants in humans."( Applicability of an in vitro digestion model in assessing the bioaccessibility of mycotoxins from food.
Oomen, AG; Rompelberg, CJ; Sips, AJ; Van de Kamp, E; Versantvoort, CH, 2005
)
0.33
" These data imply that interactions between OTA and PPs may lead to a greater bioavailability of the mycotoxin in the bloodstream with possible adverse effects for human health."( Differential modulation of ochratoxin A absorption across Caco-2 cells by dietary polyphenols, used at realistic intestinal concentrations.
De Saeger, S; Garsou, S; Larondelle, Y; Pussemier, L; Schaut, A; Schneider, YJ; Sergent, T; Van Peteghem, C, 2005
)
0.33
" These results suggest that the addition of MWF is effective in decreasing the bioavailability of OTA from contaminated diets in piglets."( Effectiveness of mycotoxin sequestration activity of micronized wheat fibres on distribution of ochratoxin A in plasma, liver and kidney of piglets fed a naturally contaminated diet.
Aoudia, N; Callu, P; Grosjean, F; Larondelle, Y, 2009
)
0.35
", 2008), mature F344 male rats presented a significantly lower OTA bioavailability than females and young animals."( Effects of fasting and gender on ochratoxin A toxicokinetics in F344 rats.
Arbillaga, L; Corcuera, LA; de Cerain, AL; Gil, AG; Gonzalez-Peñas, E; Mantle, PG; Nagy, JM; Trocóniz, IF; Vettorazzi, A, 2010
)
0.36
" Thus, the sex differences observed in organs distribution are a reflection of the differences in relative bioavailability observed in adult males, as a consequence of the fed and fasted conditions and to the significant higher body weight of mature males which directly affected the V/F and V(L,K)/F."( Kidney and liver distribution of ochratoxin A in male and female F344 rats.
Arbillaga, L; Corcuera, LA; de Cerain, AL; de Trocóniz, IF; Gil, AG; González-Peñas, E; Vettorazzi, A, 2011
)
0.37
"The aim of this paper was to evaluate the capacity of several yeast-based products, derived from baker's and brewer's yeasts, to sequester the mycotoxin ochratoxin A (OTA) and to decrease its rate of absorption and DNA adduct formation in vivo."( Assessment and characterisation of yeast-based products intended to mitigate ochratoxin exposure using in vitro and in vivo models.
Ballet, N; Fink-Gremmels, J; Hadjeba-Medjdoub, K; Pfohl-Leszkowicz, A; Schrickx, J, 2015
)
0.42
" The aim of this study was to investigate the effects of low ruminal pH on the bioavailability of 4 major mycotoxins [i."( Bioavailability of aflatoxin B
Boudra, H; Chaucheyras-Durand, F; Martin, C; Morgavi, DP; Pantaya, D; Silberberg, M; Wiryawan, KG, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The addition of 1% activated charcoal caused a slight decrease of ochratoxin A in the blood, whereas a tenfold dosage resulted in a 50% to 80% reduction. RPTEC/TERT1 cells were cultured with either the dosing vehicle (DMSO) or with exposure to one of six compounds.

ExcerptRelevanceReference
" Karyomegaly persisted for at least twelve months after nephrotoxin dosage ceased."( Persistent karyomegaly caused by Penicillium nephrotoxins in the rat.
Adatia, R; Gray, T; Mantle, PG; McHugh, KM; Turner, DR, 1991
)
0.28
" In the second experiment, two sheep fed hay and two fed grain were dosed with OA at ."( Effect of a hay and a grain diet on the bioavailability of ochratoxin A in the rumen of sheep.
Frohlich, AA; Marquardt, RR; Phillips, GD; Vitti, TG; Xiao, H, 1991
)
0.28
" The addition of 1% activated charcoal caused a slight decrease of ochratoxin A in the blood, whereas a tenfold dosage resulted in a 50% to 80% reduction of ochratoxin A levels in both blood and tissue."( [The protective effect of adsorbents against ochratoxin A in swine].
Bauer, J; Berner, H; Fischer, S; Gedek, B; Grünkemeier, A; Plank, G, 1990
)
0.28
" Bicarbonate-treated rats dosed with 20 mg/kg OA or with a combination dose of OA at 17 mg/kg and Eb at 50 mg/kg, had a lower frequency of histological lesions in kidneys, liver, lung, spleen and heart."( Protective effects of sodium bicarbonate on murine ochratoxicosis.
Albassam, M; Prior, M; Yong, S, 1987
)
0.27
" The respective lower dose levels of mycotoxins selected were judged to be about the no-effect levels for each dosed separately under the conditions of the trial."( Experimental combined aflatoxin B1 and ochratoxin A intoxication in pigs.
Seawright, AA; Tapia, MO, 1985
)
0.27
" Determinations of median lethal dose (LD50) were conducted by dosing day-old chicks and recording mortality for 10 days."( Toxicity of Aspergillus ochraceus contaminated wheat and different chemical forms of ochratoxin A in broiler chicks.
Manning, RO; Wyatt, RD, 1984
)
0.27
" While cytotoxicity assays have proven useful for establishing relative toxicity and structure function relationships within groups of fungal toxins, a drawback of in vitro bioassays is their susceptibility to variation depending on endpoint, target cell, and dosing strategy."( Cytotoxicity of nephrotoxic fungal toxins to kidney-derived LLC-PK1 and OK cell lines.
Armstrong, CL; Bondy, GS, 1998
)
0.3
" This suggested that even at a dosage of 2 mg of OA/kg of concentrate feed, considerable amounts of OA were not degraded by ruminal and intestinal microorganisms."( Metabolism and excretion of ochratoxin A fed to sheep.
Frohlich, AA; Höhler, D; Marquardt, RR; Südekum, KH; Wolffram, S, 1999
)
0.3
" When ingested as a food contaminant, OTA is very persistent in human beings with a blood half-life of 35 days after a single oral dosage due to unfavourable elimination toxicokinetics."( Ochratoxin A from a toxicological perspective.
Petzinger, E; Ziegler, K, 2000
)
0.31
" All cell types were characterized for epithelial origin and growth patterns and following optimization of dosing strategies and assay procedures, a strict study design was implemented to avoid systemic variations."( Species- and sex-specific renal cytotoxicity of ochratoxin A and B in vitro.
Dietrich, DR; Heussner, AH; O'Brien, E; Stack, ME, 2001
)
0.31
"Sublinear shapes of the dose-response curve in the low-dose range of toxicity testing are often postulated to be indicative of a no-effect threshold."( Statistical procedures to test for linearity and estimate threshold doses for tumor induction with nonlinear dose-response relationships in bioassays for carcinogenicity.
Lutz, RW; Lutz, WK; Stahel, WA, 2002
)
0.31
" During dosing period, the body weight and body weight gains significantly decreased at a higher dosage, in both individual and combined treatments."( Effect in rats of simultaneous prenatal exposure to ochratoxin A and aflatoxin B1. I. Maternal toxicity and fetal malformations.
Dwivedi, P; Sinha, N; Wangikar, PB, 2004
)
0.32
" Dose-response curves for each mycotoxin and mycotoxin combinations were generated."( Combined effects of selected Penicillium mycotoxins on in vitro proliferation of porcine lymphocytes.
Bernhoft, A; Flåøyen, A; Keblys, M; Larsen, HJ; Morrison, E, 2004
)
0.32
" DNA adducts found in the kidneys of mice and rats dosed with OTA, did not contain fragments of OTA."( Ochratoxin A: previous risk assessments and issues arising.
Larsen, JC; Walker, R, 2005
)
0.33
" Principal component analysis and orthogonal projection to latent structures discriminate analysis (OPLS-DA) based on GC/MS and 1H NMR data discriminated controls from animals dosed with 210 microg/kg body wt OTA as early as 14 days and animals dosed with 70 microg/kg body wt 28 days after the start of treatment, correlating with mild histopathological changes in the kidney."( Metabonomic study of ochratoxin a toxicity in rats after repeated administration: phenotypic anchoring enhances the ability for biomarker discovery.
Amberg, A; Dekant, W; Mally, A; Rached, E; Sieber, M; Wagner, S, 2009
)
0.35
" We present experimental data to complement already published and to complete dose-response findings for dietary OTA."( Lifetime, low-dose ochratoxin A dietary study on renal carcinogenesis in male Fischer rats.
Kulinskaya, E; Mantle, P, 2010
)
0.36
" RPTEC/TERT1 cells were cultured with either the dosing vehicle (DMSO) or with exposure to one of six compounds (nifedipine, potassium bromate, monuron, D-mannitol, ochratoxin A and sodium diclofenac), several of which are known to cause renal effects."( Metabolic response to low-level toxicant exposure in a novel renal tubule epithelial cell system.
Athersuch, TJ; Cavill, R; Ebbels, TM; Ellis, JK; Jennings, P; Keun, HC; McMorrow, T; Radford, R; Ryan, MP; Slattery, C, 2011
)
0.37
"5% of dosage (maximum 10%)."( Ochratoxin A in ruminants−A review on its degradation by gut microbes and effects on animals.
Blank, R; Hummel, J; Mobashar, M; Südekum, KH, 2010
)
0.36
" The proposed MoA is critically assessed with respect to concordance of dose-response of the suggested key events and tumor formation, their temporal association, consistency, and biological plausibility."( Ochratoxin a and mitotic disruption: mode of action analysis of renal tumor formation by ochratoxin A.
Mally, A, 2012
)
0.38
" Generally, OTA removal achieved in all treatments was higher when the adsorbent dosage increased, but the impact on wine quality also was higher."( Ochratoxin A removal from red wine by several oenological fining agents: bentonite, egg albumin, allergen-free adsorbents, chitin and chitosan.
Elejalde, E; López De Armentia, I; Quintela, S; Villarán, MC, 2012
)
0.38
" By analyzing data with nonlinear regression, toxins applied singly showed classic sigmoid dose-response curves in HepG2 cells whereas in KK-1 cells hormetic responses were observed."( Analysis of individual and combined effects of ochratoxin A and zearalenone on HepG2 and KK-1 cells with mathematical models.
Cheng, WH; He, X; Huang, K; Li, Y; Liang, R; Luo, H; Luo, Y; Xu, W; Zhang, B, 2014
)
0.4
" Our results showed that OTA can cause cell damage through several mechanisms and that the OTA exposure time is more important that the dosage in in vitro studies."( UPLC-MS/MS analysis of ochratoxin A metabolites produced by Caco-2 and HepG2 cells in a co-culture system.
González-Arias, CA; Marín, S; Ramos, AJ; Rojas-García, AE; Sanchis, V, 2017
)
0.46
" The results show that utilising a 2839 gene panel, it is possible to discriminate basal tissue-specific signatures, generate dose-response relationships and to discriminate compound-specific and cell type-specific responses."( Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq.
Ates, G; Carta, G; Jennings, P; Limonciel, A; Seligmann, B; Shepard, PJ; van de Water, B; VanSteenhouse, HC; Vinken, M; Watzele, M; Wilmes, A; Yeakley, JM, 2018
)
0.48
" BEA showed a weak antagonistic effect at the androgen receptor and OTA produced a biphasic dose-response curve at the estrogen receptor."( Cytotoxicity against fish and mammalian cell lines and endocrine activity of the mycotoxins beauvericin, deoxynivalenol and ochratoxin-A.
Fernández-Cruz, ML; García-Herranz, V; Navas, JM; Valdehita, A, 2019
)
0.51
" Its preparation parameters such as the time of photo-initiation, the dosage of photo-initiator and the concentration of aptamer were investigated in detail."( A double-recognized aptamer-molecularly imprinted monolithic column for high-specificity recognition of ochratoxin A.
Li, J; Lyu, H; Sun, H; Wang, J; Xie, Z; Zhu, Y, 2020
)
0.56
" However, it is unknown whether the lower dosage of FB1 aggravates the toxicity of other mycotoxins."( Non-cytotoxic dosage of fumonisin B1 aggravates ochratoxin A-induced nephrocytotoxicity and apoptosis via ROS-dependent JNK/MAPK signaling pathway.
Gan, F; Huang, K; Kang, W; Li, H; Lin, Z; Wang, M, 2021
)
0.62
"This study applied multi-mycotoxin liquid chromatography with tandem mass spectrometric detection (LC-MS/MS) methods to determine the biomarkers of exposure in urine and serum samples from a dose-response study with pigs."( Biomarkers of Deoxynivalenol, Citrinin, Ochratoxin A and Zearalenone in Pigs after Exposure to Naturally Contaminated Feed Close to Guidance Values.
Dąbrowski, M; Jedziniak, P; Ochodzki, P; Rudawska, A; Tkaczyk, A; Zielonka, Ł, 2021
)
0.62
" 2'R-OTA dosage did not reduce parameters chick quality compared to chicks hatched from control group eggs."( Toxico-pathological effects of ochratoxin A and its diastereoisomer under in ovo conditions and in vitro evaluation of the toxicity of these toxins against the embryo Gallus gallus fibroblast cell line.
Bryła, M; Chmiel, M; Damaziak, K; Pierzgalski, A; Roszko, M; Soszczyńska, E; Stępień, Ł; Twarużek, M; Waśkiewicz, A; Wójcik, W; Łukasiewicz-Mierzejewska, M, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
calcium channel blockerOne of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools.
mycotoxinPoisonous substance produced by fungi.
nephrotoxinA poison that interferes with the function of the kidneys.
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
teratogenic agentA role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect.
Aspergillus metaboliteAny fungal metabolite produced during a metabolic reaction in the mould, Aspergillus.
Penicillium metaboliteAny fungal metabolite produced during a metabolic reaction in Penicillium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
phenylalanine derivativeAn amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of phenylalanine by a heteroatom. The definition normally excludes peptides containing phenylalanine residues.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
isochromanes
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
N-acyl-L-phenylalanineAny N-acyl-L-amino acid obtained by the formal N-acylation of L-phenylalanine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency25.11895.623417.292931.6228AID485281
AR proteinHomo sapiens (human)Potency31.35400.000221.22318,912.5098AID588515; AID588516
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.02680.000214.376460.0339AID588532; AID588533
farnesoid X nuclear receptorHomo sapiens (human)Potency23.04040.375827.485161.6524AID588526; AID588527
estrogen nuclear receptor alphaHomo sapiens (human)Potency38.14560.000229.305416,493.5996AID588513; AID588514
glucocerebrosidaseHomo sapiens (human)Potency31.62280.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency42.23950.001024.504861.6448AID588534; AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency1.27880.001019.414170.9645AID588536; AID588537
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency28.62880.023723.228263.5986AID588541; AID588543
alpha-galactosidaseHomo sapiens (human)Potency27.71704.466818.391635.4813AID1467; AID2107
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency35.48130.036619.637650.1187AID2112
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency24.56760.010039.53711,122.0200AID588545; AID588547
nuclear factor NF-kappa-B p105 subunit isoform 1Homo sapiens (human)Potency44.66844.466824.832944.6684AID651749
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency36.01360.000627.21521,122.0200AID651741; AID720636
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency19.11800.00798.23321,122.0200AID2546; AID2551
Cellular tumor antigen p53Homo sapiens (human)Potency0.89130.002319.595674.0614AID651743
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency17.78281.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 20Mus musculus (house mouse)Ki48.98901.10006.67899.1201AID360149
Solute carrier family 22 member 6Mus musculus (house mouse)Ki6.25480.40745.02179.4000AID360150
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)58.00002.41006.343310.0000AID679666
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 6Rattus norvegicus (Norway rat)Km1.33500.57001.33502.1000AID681739; AID681744
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Km22.80000.01503.49967.0000AID680235; AID682135
Solute carrier organic anion transporter family member 1A3Rattus norvegicus (Norway rat)Km11.10001.00004.43338.5000AID681577; AID681578
Solute carrier family 22 member 6Homo sapiens (human)Km0.42000.42004.61839.3000AID679378
Solute carrier family 22 member 8Homo sapiens (human)Km0.75000.34501.32173.1000AID681030
Solute carrier family 22 member 19Mus musculus (house mouse)Km2.00002.00002.00002.0000AID678844
Solute carrier family 22 member 11Homo sapiens (human)Km22.90000.15400.62151.0100AID680163
Solute carrier family 22 member 8Rattus norvegicus (Norway rat)Km0.73900.73901.53952.3400AID678967
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (150)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
monoatomic anion transportSolute carrier family 22 member 6Homo sapiens (human)
response to organic cyclic compoundSolute carrier family 22 member 6Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 6Homo sapiens (human)
organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transportSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transportSolute carrier family 22 member 6Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 6Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 6Homo sapiens (human)
renal tubular secretionSolute carrier family 22 member 6Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 8Homo sapiens (human)
response to toxic substanceSolute carrier family 22 member 8Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 8Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 8Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 8Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 11Homo sapiens (human)
inorganic anion transportSolute carrier family 22 member 11Homo sapiens (human)
organic anion transportSolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 11Homo sapiens (human)
urate metabolic processSolute carrier family 22 member 11Homo sapiens (human)
transmembrane transportSolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (51)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
protein bindingSolute carrier family 22 member 6Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
alpha-ketoglutarate transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
antiporter activitySolute carrier family 22 member 6Homo sapiens (human)
transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
chloride ion bindingSolute carrier family 22 member 6Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 6Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 6Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 8Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 8Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
solute:inorganic anion antiporter activitySolute carrier family 22 member 11Homo sapiens (human)
protein bindingSolute carrier family 22 member 11Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytosolL-cysteine:1D-myo-inositol 2-amino-2-deoxy-alpha-D-glucopyranoside ligaseMycobacterium tuberculosis H37Rv
plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
caveolaSolute carrier family 22 member 6Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 6Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 6Homo sapiens (human)
protein-containing complexSolute carrier family 22 member 6Homo sapiens (human)
plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 8Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 8Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
external side of plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 11Homo sapiens (human)
extracellular exosomeSolute carrier family 22 member 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID681030TP_TRANSPORTER: uptake in OAT3-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID590639Inhibition of Mycobacterium tuberculosis recombinant MBP-tagged MshC assessed as formation of fluorescently labeled Cys-GlcN-Ins by HPLC2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Susceptibility and mode of binding of the Mycobacterium tuberculosis cysteinyl transferase mycothiol ligase to tRNA synthetase inhibitors.
AID360153Activity of mouse Oat1 expressed in Xenopus oocytes assessed as drug uptake2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID682135TP_TRANSPORTER: uptake in Oatp1-expressing CHO-03 cell1999The American journal of physiology, 04, Volume: 276, Issue:4
Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells.
AID678967TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The Journal of biological chemistry, May-07, Volume: 274, Issue:19
Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain.
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID681577TP_TRANSPORTER: uptake in OAT-K2-expressing MDCK cells2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID680235TP_TRANSPORTER: uptake in Xenopus laevis oocytes1996The Journal of pharmacology and experimental therapeutics, Dec, Volume: 279, Issue:3
Uptake of the mycotoxin ochratoxin A in liver cells occurs via the cloned organic anion transporting polypeptide.
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID456115Cytotoxicity against human HepG2 cells after 48 hrs by WST8 assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Total synthesis and cytotoxicity evaluation of all ochratoxin A stereoisomers.
AID678971TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of biological chemistry, Feb-11, Volume: 275, Issue:6
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID456116Induction of apoptosis in human HepG2 cells assessed as caspase 3 activation after 24 hrs by fluorescence assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Total synthesis and cytotoxicity evaluation of all ochratoxin A stereoisomers.
AID679378TP_TRANSPORTER: uptake in OAT1-expressing S2 cells2001Life sciences, Sep-21, Volume: 69, Issue:18
Characterization of ochratoxin A transport by human organic anion transporters.
AID680163TP_TRANSPORTER: uptake in OAT4-expressing S2 cells2002Biochimica et biophysica acta, Jun-12, Volume: 1590, Issue:1-3
Role of human organic anion transporter 4 in the transport of ochratoxin A.
AID681578TP_TRANSPORTER: uptake in OAT-K1-expressing MDCK cells2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.
AID679666TP_TRANSPORTER: inhibition of PAH uptake (PAH: 0.1uM) in membrane vesicles from MRP2-expressing HEK cells2000Kidney international, Apr, Volume: 57, Issue:4
ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2.
AID456117Cytotoxicity against human HepG2 cells assessed as LDH release after 48 hrs by microplate reader method2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Total synthesis and cytotoxicity evaluation of all ochratoxin A stereoisomers.
AID679695TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 0.25 uM, OTA: 100 uM) in OAT-K1-expressing MDCK cells2001The Journal of pharmacology and experimental therapeutics, Oct, Volume: 299, Issue:1
Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.
AID678844TP_TRANSPORTER: uptake in Oat5-expressing oocytes2004American journal of physiology. Renal physiology, Aug, Volume: 287, Issue:2
Identification and functional assessment of the novel murine organic anion transporter Oat5 (Slc22a19) expressed in kidney.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID681739TP_TRANSPORTER: uptake in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, Jun, Volume: 289, Issue:3
Transport of ochratoxin A by renal multispecific organic anion transporter 1.
AID681141TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001Molecular pharmacology, May, Volume: 59, Issue:5
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
AID681371TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Molecular pharmacology, Jul, Volume: 62, Issue:1
Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice.
AID360152Activity of mouse Oat6 expressed in Xenopus oocytes assessed as drug uptake2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID681744TP_TRANSPORTER: uptake in OAT1-expressing S1 cells1999The Journal of pharmacology and experimental therapeutics, Jun, Volume: 289, Issue:3
Transport of ochratoxin A by renal multispecific organic anion transporter 1.
AID679663TP_TRANSPORTER: uptake in membrane vesicles from MRP2-expressing HEK cells2000Kidney international, Apr, Volume: 57, Issue:4
ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,037)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990205 (6.75)18.7374
1990's315 (10.37)18.2507
2000's802 (26.41)29.6817
2010's1220 (40.17)24.3611
2020's495 (16.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (0.57%)5.53%
Reviews221 (6.97%)6.00%
Case Studies6 (0.19%)4.05%
Observational0 (0.00%)0.25%
Other2,925 (92.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]